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Objective:  To determine whether systemic juvenile idiopathic arthritis (sJIA) 
susceptibility loci identified by candidate gene studies demonstrated association with 
sJIA in the largest study population assembled to date. 
Methods:  Single nucleotide polymorphisms (SNPs) from 11 previously reported sJIA 
risk loci were examined for association in 9 populations, including 770 sJIA cases and 
6947 control subjects. The effect of sJIA-associated SNPs on gene expression was 
evaluated in silico in paired whole genome and RNA sequencing data from 
lymphoblastoid cell lines (LCL) of 373 European 1000 Genomes Project subjects. The 
relationship between sJIA-associated SNPs and response to anakinra treatment was 
evaluated in 38 US patients for whom treatment response data were available. 
Results:  We found no association of the 26 SNPs previously reported as sJIA-
associated.  Expanded analysis of the regions containing the 26 SNPs revealed only 
one significant association, the promoter region of IL1RN (p<1E-4). sJIA-associated 
SNPs correlated with IL1RN expression in LCLs, with an inverse correlation between 
sJIA risk and IL1RN expression. The presence of homozygous IL1RN high expression 
alleles correlated strongly with non-response to anakinra therapy (OR 28.7 [3.2, 255.8]). 
Conclusion:  IL1RN was the only candidate locus associated with sJIA in our study. 
The implicated SNPs are among the strongest known determinants of IL1RN and IL1RA 
levels, linking low expression with increased sJIA risk. Homozygous high expression 
alleles predicted non-response to anakinra therapy, nominating them as candidate 
biomarkers to guide sJIA treatment.  This is an important first step towards the 
personalized treatment of sJIA. 
Systemic juvenile idiopathic arthritis (sJIA) is a rare, severe childhood inflammatory 
disease1, 2 that develops in the absence of an identifiable cause.  sJIA is marked by the 
presence of chronic arthritis that occurs in the context of profound systemic 
inflammation, including quotidian fever, lymphadenopathy, hepatosplenomegaly, a 
salmon pink evanescent skin rash and serositis.  It may also be accompanied by life 
threatening complications, including pericardial effusion, interstitial lung disease, 
amyloidosis, and macrophage activation syndrome, a highly lethal secondary form of 
hemophagocytic lymphohistiocytosis.  Among children with sJIA, approximately half 
develop a destructive form of chronic arthritis that persists throughout their lives. 
Despite its unifying inflammatory characteristics, sJIA is a heterogeneous condition with 
three distinct disease courses and variable expression of clinical manifestations and 
complications3.  Regardless of the disease course and specific manifestations, the goal 
of sJIA treatment is to extinguish the systemic inflammation as rapidly as possible, 
taking advantage of the early therapeutic “window of opportunity” in an effort to avoid 
the development of persistent arthritis4.  Achievement of this goal is often complicated 
by the fact that children with sJIA do not respond uniformly to the currently available 
therapies5, 6.  A subset of sJIA responds to treatments targeting interleukin (IL)-1, a 
subset responds to IL-6 directed therapies, a subset responds to tumor necrosis factor 
(TNF)-α blockade, and a subset does not respond to any of these treatment strategies.  
Importantly, there is no objective determinant or biomarker that assists in predicting 
which therapeutic approach will be successful in individual patients, and thus there are 
often delays in ameliorating the systemic inflammation. 
The pathophysiology of sJIA is poorly understood, as is the basis of its phenotypic 
heterogeneity. Due to its rare nature, most genetic studies of sJIA have utilized a 
candidate gene approach to examine small case-control collections.  These studies 
produced a list of over two dozen single nucleotide polymorphisms (SNPs) at 11 distinct 
susceptibility loci that were reported as sJIA-associated loci.  These include the 
IL1A/B7,8, GLI27, IL1RN/PSD47, IL1R27, IL10/209,10, IL611,12, MVK8, CCR513, MIF14, 
SLC26A215, and TAPBP16 loci (Table 1).  Importantly, the original evidence supporting 
these associations was modest, and in many cases, the associations were not observed 
in studies of independent populations.  Despite these facts, these associations are 
regularly included in discussions of sJIA pathophysiology. 
 
We have recently performed the largest genetic study of sJIA, a multi-national effort that 
included children with sJIA from 9 countries17,18.  We identified two bona fide sJIA 
susceptibility loci and 24 additional loci suggestively associated with sJIA, however 
there was no overlap between the peak sJIA susceptibility loci in our studies and those 
reported in the earlier candidate gene studies.  To evaluate the relationship between 
sJIA risk and the sJIA susceptibility loci identified by candidate gene studies, we have 
undertaken a regional association study of the 11 reported candidate susceptibility loci 
in the International Childhood Arthritis Genetics Consortium (INCHARGE) sJIA case-
control collection.  
  
Materials and Methods 
Study design and participants 
Directly observed and imputed SNP genotype data from the 9 case-control populations 
of the INCHARGE sJIA collection were evaluated for this study17,18.  The INCHARGE 
sJIA collection includes children fulfilling International League of Associations for 
Rheumatology (ILAR) criteria for sJIA and control subjects from the United States, the 
United Kingdom, Germany, Turkey, Italy, Brazil, Argentina, Canada and Spain.  SNP 
genotyping of genomic DNA from cases and controls was performed using Human 
Omni1M arrays and an iScan reader (Illumina).  SNP genotypes were stratified by 
country of origin and, where available, combined with existing SNP genotype datasets, 
in silico, from geographically-matched healthy control individuals.  Each geographically-
defined stratum was subjected to rigorous quality control processes to remove samples 
and SNPs of poor quality using standard metrics.  Ancestral outliers were removed from 
each geographically-defined stratum using a combination of principal components 
analysis and multidimensional scaling.  The degree of matching was assessed using 
genomic control inflation factors (λGC), which were < 1.004 for each of the 9 strata.  
Detailed information about case and control populations included in the INCHARGE 
collection, along with technical descriptions and visualizations of the quality control 
processes and their results can be found in the supplementary material of our earlier 
papers17,18.  For the present study, genotypes of SNPs residing in 11 candidate loci 
(Tables S1) were examined in 770 children with sJIA and 6947 control samples from the 
United States, the United Kingdom, Germany, Turkey, Italy, Brazil, Argentina, Canada 
and Spain.  For candidate loci defined by a single sJIA-associated SNP, the study 
interval was defined as ± 100 kilobases (Kb) from the position of that SNP.  When more 
than one SNP association was present within a locus, the study interval was defined as 
± 100 Kb from the mean of the positions of the reported sJIA-associated SNPs.  
 
Statistical analysis 
Association testing of candidate SNPs was performed under the additive model, 
adjusted for sex and ancestry-informative principal components, in each of the 9 sJIA 
case-control collections using SNPTESTv219.  Association results were then combined 
across collections using fixed-effect meta-analysis with GWAMA software20. 
Heterogeneity was evaluated using the i2 statistic and SNPs exhibiting moderate 
evidence of heterogeneity (i2 > 0.5) were excluded from our analysis.  Association data 
were visualized using SNP and Variation Suite 8 (SVS8, Golden Helix, Bozeman, 
Montana) and custom R scripts (R version 3.4.0).  Haplotype analysis and examination 
of LD were performed using Haploview21.  The SNP set was pruned for pairwise linkage 
disequilibrium (LD) of r2 < 0.5 by the Estimation-Maximization method with PLINK22 to 
determine the number of independent SNPs in the study.  The threshold for study-wide 
significance was defined by a Bonferroni correction for the total number of independent 
SNPs across all candidate loci. 
 
Gene expression analysis 
The effect of sJIA-associated SNPs on gene and/or protein expression was examined 
using the Haploregv4.1 database23. The correlation of sJIA-associated SNPs with gene 
expression was investigated by an integrated examination of RNA-sequencing (RNA-
seq) and whole genome sequencing (WGS) data from 1000 Genomes Project 
subjects24,25.  RNA-seq data from the set of 373 lymphoblastoid cell lines (LCLs) of 
European 1000 Genomes Project subjects were downloaded from the Geuvadis 
website (http://www.geuvadis.org/web/geuvadis/RNAseq-project) and WGS data from 
the corresponding individuals was downloaded from the 1000 Genomes Project website 
(http://www.internationalgenome.org/data/).  RNA-seq data (normalized reads per 
kilobase per million reads or RPKM) were stratified by sJIA risk allele genotype and the 
difference in relative expression between genotypes was evaluated using the non-
parametric Kruskal-Wallis test.  Box plots of relative expression were generated using 
R. 
 
Therapeutic response analysis 
The relationship between sJIA-associated IL1RN SNPs and therapeutic response to 
human recombinant IL-1RA (anakinra) or tocilizumab treatment was examined in sJIA 
patients from the U.S. stratum for whom therapeutic response data were available.  This 
included 38 anakinra treated subjects and 14 subjects treated with tocilizumab.  
Treatment response data were extracted from medical records by the treating pediatric 
rheumatologist, who encoded either “no response” or “any response” for each subject.  
“No response” was defined as no improvement of either fever (if present) or arthritis.  
“Any response” was defined as any degree of improvement in either fever or arthritis.  
Treatment response was then tested for association with sJIA-associated SNPs by 
logistic regression under the dominant model using SVS8.  The threshold of significance 
for the association test was defined by a Bonferroni correction for the number of 
independent SNPs tested, as defined by pairwise LD pruning (r2 < 0.5). 
 Results 
Association testing of sJIA candidate SNPs and loci 
We first performed association testing of the 26 SNPs for which associations with sJIA 
had been previously reported (Table 1).  After applying Bonferroni correction for 26 
SNPs, association meta-analysis of the 9 INCHARGE sJIA study populations revealed 
no significant associations with sJIA (p < 0.05 ÷ 26 = 1.9 x 10-3, Table 1, Figure S1).  To 
evaluate whether the 11 candidate loci containing these 26 SNPs harbored sJIA risk 
SNPs distinct from those previously described, we extended our analysis to test all 
SNPs within these candidate risk loci for association with sJIA. The candidate regions 
included a total of 5479 SNPs (Table S2), but LD pruning at a level of r2 < 0.5 
determined that only 500 of them were independent.  This defined the threshold of 
study-wide significance (p < 0.05 ÷ 500 = 1.0 x 10-4).  By this standard, association 
meta-analyses of these 11 loci revealed a single significant association signal within the 
IL1RN locus (Figure 1).  The association peak was located 4.3 Kb upstream from 
IL1RN, with 3 SNPs exceeding the significance threshold and the top 7 SNPs in strong 
LD with one another (Figure 2).  In fact, LD mapping and haplotype analysis of the top 
25 SNPs within this locus revealed that the top 7 sJIA-associated SNPs were inherited 
as a part of a common haplotype (Figure 2). 
 
sJIA-associated IL1RN variants and gene expression 
A query of the HaploRegv4.1 database revealed that many of the top sJIA-associated 
SNPs were known expression quantitative trait loci (eQTL) for IL1RN in whole blood26 
and LCLs25 (Table 2). Moreover, a review of the literature found that sJIA-associated 
SNPs also correlated with IL-1RA protein levels in the largest study of genetic predictors 
of IL-1RA levels27.  The SNP that most strongly correlated with IL-1RA in that study, 
rs4251961, was one of the top sJIA-associated SNPs and was a constituent of the 7 
SNP haplotype (Figure 2, Table 2). These observations were corroborated by our direct 
analyses of LCL RNA-seq data from 1000 Genomes Project subjects25, which found 
that the sJIA-associated SNPs were strongly correlated with IL1RN expression (Figures 
3 and S2).  Specifically, alleles that were protective against sJIA correlated with high 
IL1RN expression and those that were risk factors for sJIA correlated with reduced 
IL1RN expression (Figure 3).  Importantly, all three of the studies mentioned above 
parsimoniously demonstrated that sJIA risk alleles of the top 42 sJIA-associated SNPs 
were correlated with decreased levels of IL1RN expression or circulating IL-1RA protein 
(Figure 3). 
 
sJIA-associated IL1RN variants and response to anakinra therapy in sJIA 
Given that the response of sJIA to treatment with recombinant human IL-1RA (anakinra) 
is variable, we hypothesized that individuals with the highest genetically-encoded levels 
of IL-1RA may fail to respond to anakinra treatment more often than those with lower 
genetically-encoded levels.  To evaluate this possibility, we examined clinical and SNP 
genotype data in 38 sJIA patients from the U.S. collection that had received anakinra 
and for whom clinical data were available.  Within this group of anakinra treated 
subjects, there were 9 non-responders and 29 “any responders”.  An examination of the 
top 7 sJIA-associated IL1RN SNPs found that for each SNP, homozygosity for the 
IL1RN high expression alleles was associated with non-response to anakinra treatment 
(p < 0.05, Table 3).  rs555447483 showed the strongest association with anakinra non-
response (p = 7.7 x 10-4; OR 28.7 [3.2, 255.8], with homozygous high expression alleles 
predicting non-response with a sensitivity of 92% and a specificity of 71%. 
 
To determine whether the relationship between these SNPs and sJIA treatment failure 
were specific to anakinra, we performed an identical examination of the 14 sJIA patients 
from the U.S. collection who were treated tocilizumab, an anti-IL-6 monoclonal antibody.  
Within this group, which included 3 tocilizumab non-responders and 11 tocilizumab “any 
responders,” we found no association between sJIA-associated IL1RN SNPs and 
response to tocilizumab treatment (Table S3).  Moreover, 8 of the 14 patients treated 
with tocilizumab were anakinra non-responders who received tocilizumab as second 
line treatment.  Among the 8 anakinra non-responders, 6 were tocilizumab “any 
responders.”  Taken together, these facts support the hypothesis that sJIA-associated 
IL1RN SNPs specifically predict non-response of sJIA to anakinra treatment, as 
opposed to identifying individuals whose sJIA is more broadly refractory to treatment.   
 
Discussion 
Through an examination of common genetic variants at 11 previously reported sJIA 
susceptibility loci in the INCHARGE sJIA collection, this study has yielded three 
important observations.  First, this study has demonstrated that the IL1RN locus is a 
bona fide sJIA susceptibility locus.  Second, it has revealed that genetically-encoded 
high expression of IL1RN and production of IL-1RA are protective against sJIA (and 
conversely that genetically-encoded low expression/production are risk factors for 
developing sJIA.)  Most importantly, it has shown that homozygosity for the high 
expression alleles of sJIA-associated IL1RN SNPs is strongly associated with 
unresponsiveness to anakinra treatment in sJIA patients.  
 
The original studies describing these 11 candidate loci reported modest associations 
that were identified in small case-control collections7-16.  At most of these loci, the 
associations with sJIA were not observed in subsequent studies of other populations, 
calling their proposed relationships with sJIA into question.  We sought to evaluate 
these associations more rigorously by using the INCHARGE sJIA collection, which 
provided greater statistical power than any previous study of these loci while also 
allowing for internal validation through the examination of 9 independent populations.  
Using this approach, we found that only one of these candidate loci, IL1RN, was 
associated with sJIA.  At this locus, we observed 3 sJIA-associated SNPs that tagged a 
7 SNP haplotype in the promoter region of IL1RN, as well as a cluster of 39 other SNPs 
with intermediate evidence of association with sJIA.  Importantly, the IL1RN association 
signal identified in the present study did not include any of the SNPs that were 
previously reported as sJIA-associated (Table 1) or any SNPs that were in strong LD 
with those SNPs (Figures 1 and S1).  This observation suggests that the historical 
candidate gene studies of sJIA could have been negatively impacted by poor statistical 
power, as has been the case in other genetically complex diseases, such as 
schizophrenia28.  
 
Given that the association signal of the IL1RN locus was within the promoter region, we 
hypothesized that these SNPs may influence sJIA risk by altering gene expression.  By 
examining previously published gene expression studies and integrating our association 
data with publicly available gene expression datasets, we found that the risk alleles of 
the top 42 sJIA-associated IL1RN SNPs correlated with reduced IL1RN expression and 
circulating IL-1RA levels (Figure 2, Table 2).  Furthermore, we observed that the top 7 
sJIA-associated SNPs were among the SNPs most strongly associated with IL1RN 
expression levels in whole blood and LCLs, and with circulating levels of IL-1RA protein, 
in published studies (Table 2)25-27.  Taken together these observations suggest that the 
sJIA-associated IL1RN SNPs influence sJIA risk through their effect on IL1RN 
expression and production of IL-1RA.   
 
IL-1RA is a well-documented positive acute phase protein29 and it has been shown to 
be highly expressed in the blood of children with active sJIA30-31.  Therefore, one would 
expect that gene expression studies should find increased expression of IL1RN in 
children with active sJIA compared to healthy subjects or children with quiescent sJIA.  
There have been several studies that have examined gene expression in sJIA 
peripheral blood mononuclear cells.  In one of these studies, the expression of positive 
acute phase genes was upregulated in children with sJIA and the authors noted that 
IL1RN was among this cluster32.  However, three other studies found no relationship 
between sJIA and IL1RN expression33-35. There are a couple of potential reasons for 
these conflicting results.  These studies were undertaken in relatively small numbers of 
sJIA cases, so it is possible that they lacked the statistical power to identify a 
relationship between sJIA and IL1RN expression.  It is also possible that these studies 
were affected by confounding variables that altered IL1RN expression in the sJIA 
patients, such as the duration of sJIA, the level of sJIA disease activity or the 
treatment(s) administered for sJIA.  By examining the correlation between sJIA-
associated IL1RN variants and gene expression in healthy individuals, the present study 
could identify the relationship between IL1RN expression and sJIA without the 
interference of these potential confounders. 
 
Looking beyond disease risk, we also observed that high expression alleles of sJIA-
associated IL1RN SNPs were strongly associated with non-response to anakinra 
therapy.  The lack of association between these SNPs and non-response to tocilizumab 
treatment suggests that these SNPs are specifically associated with anakinra non-
responsiveness, as opposed to being associated with more global therapeutic 
recalcitrance.  In the context of the bi-phasic hypothesis of sJIA pathophysiology, new 
onset sJIA is treated with the goal of rapidly inducing remission within the therapeutic 
window of opportunity4.  Anakinra is commonly chosen as the first line treatment 
because its effects can be observed within days of initiation and because its dosing can 
be rapidly escalated, but it is not effective in all patients36.  In the subset of sJIA cases 
that ultimately don’t respond to anakinra, their time to remission is extended by the 
failed therapeutic course of anakinra.  The findings of this study can be used to identify 
the subset of children with sJIA that are unlikely to respond to anakinra and facilitate the 
selection of an alternative treatment.  In doing so, one can avoid the delay associated 
with a first-line therapeutic failure and reduce the time to remission, as well as prevent 
unnecessary exposure to the risks of anakinra treatment.  This is the first candidate 
biomarker that can prospectively guide therapeutic decision making in sJIA. 
 
Despite the strength of our findings, it is important to consider potential limitations of our 
study.  This study evaluated genetic associations in 9 independent sJIA case-control 
collections.  It will be important to examine the IL1RN region in larger, independent 
groups of patients.  There were several limitations to the evaluation of genetic predictors 
of anakinra response.  Therapeutic response to anakinra was examined in 38 sJIA 
patients, which is a relatively small group.  The anakinra treated patients were not 
treated in a standardized fashion, with potential variation in the drug dosing and 
duration, timing of dose escalation and co-administration of other agents (ie. 
glucocorticoids).  The clinical response data were extracted from medical records in a 
post hoc analysis and clinical response metrics were not standardized.  We anticipated 
that these factors would complicate differentiating incomplete and complete response, 
but should not influence the identification of non-response.  Therefore, we chose to 
compare non-response to “any response.”  Nonetheless, it will be important to evaluate 
the correlation between IL1RN SNPs and response to anakinra in prospective studies of 
larger numbers of patients treated and monitored in a standardized manner. 
  
By identifying a prospective biomarker capable of guiding the treatment of sJIA, this 
study brings precision medicine to the rheumatology clinic.  Looking forward, it will be 
important to determine whether these findings are generalizable beyond anakinra and 
sJIA.  For example, can the IL1RN SNPs predict therapeutic response with other IL-1 
directed therapies, such as monoclonal anti-IL-1β antibodies (canakinumab) or the IL-1 
trap (rilonacept), in sJIA.  Similarly, these SNPs may predict therapeutic response to 
anakinra (or other IL-1 directed therapies) in conditions other than sJIA, such as adult-
onset Still’s disease or monogenic autoinflammatory diseases.  Given that recently 
published trials have found that canakinumab treatment significantly reduces the risk of 
recurrent cardiovascular events37, as well as the incidence of and mortality from lung 
cancer38, it is even possible that the utility of this prospective biomarker may extend 
beyond the field of rheumatology. 
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Figure Legends 
Figure 1. INCHARGE sJIA case-control regional association plots of loci 
previously implicated by candidate gene studies. Regional association plots for 
previously reported sJIA candidate susceptibility loci near IL1A/B (A), GLI2 (B), 
IL1RN/PSD4 (C), IL1R2 (D), IL10/20 (E), IL6 (F), MVK (G), CCR5 (H), MIF (I), 
SLC26A2 (J), and TAPBP (K) show minimal significance in INCHARGE case-control 
dataset, except for a cluster of SNPs in the IL1RN/PSD4 region (C). None of the top 
SNPs from previous candidate studies (labeled and denoted by red diamonds) showed 
even nominal significance with sJIA. Other SNPs in the candidate loci are shown as 
blue circles. The brown horizontal line demonstrates the study-wide significance 
threshold.  
 
Figure 2. Variants of the IL1RN locus are associated with sJIA in the INCHARGE 
case-control collection. SNP associations within the IL1RN locus are shown, colored 
by pairwise linkage disequilibrium (LD) with the most strongly associated SNP, 
rs55663133 (A). The brown horizontal line demonstrates the study-wide significance 
threshold. In Panel B, a forest plot demonstrates the effect size of rs55663133 by meta-
analysis and in individual study populations. Panel C displays pairwise LD with the peak 
sJIA-associated SNP, rs55663133 (star) in the U.S. case-control population.  The top 7 
sJIA associated markers (19-25) form a strong LD block. 
 
Figure 3. Relationship of IL1RN expression and IL-1RA protein levels with sJIA-
associated SNPs. IL1RN expression by RNA sequencing from the study of 
Lappalainen et al.25 is shown, stratified by genotype, for representative sJIA-associated 
SNPs (A and B). Dot plots depict all SNPs with reported correlations with IL1RN 
expression (C and D) or IL-1RA protein levels (E) in the studies by Westra et al.26, 
Lappalainen et al.25, and Herder et al.27, respectively. SNPs among the top 42 sJIA-
associated SNPs are highlighted in green (sJIA protective alleles) and gold (sJIA risk 




Table 1.  Association results of 26 systemic juvenile idiopathic arthritis candidate SNPs in INCHARGE sJIA study collection  
   Previous Study INCHARGE Study 
Previous Study SNP Gene P value OR (95 C.I.) P value OR (95 C.I.) i
2
 N / n 
Stock et. al. 
rs6712572 IL1 Ligand (CKAP2L) 0.0045 1.62 (1.16, 2.29) 0.66 1.03 (0.91, 1.15) 0.34 9/7708 
rs2071374 IL1 Ligand (IL1A) 0.0060 1.65 (1.15, 2.37) 0.11 1.11 (0.98, 1.25) 0 9/7711 
rs3783516 IL1 Ligand (IL1A/IL1B) 0.0053 1.64 (1.15, 2.27) 0.04 1.13(0.80, 1.26) 0.30 9/7711 
rs4848123  IL1 Ligand (GLI2) 0.0030 1.70 (1.19, 2.44) 0.24 0.27 (0.12, 2.38) 0.80 2/449 
rs3917368 IL1 Ligand (IL1B) 0.0096 1.57 (1.11, 2.22) 0.18 1.08 (0.96, 1.22) 0.43 9/7715 
rs1688075 IL1 Ligand (IL1RN) 0.0089 3.04 (1.58, 5.85) 0.64 0.95 (0.77, 1.17) 0.06 8/7603 
rs4849159 IL1 Ligand (PSD4) 0.040 1.61 (1.02, 2.54) 0.17 0.89 (0.75, 1.05) 0 8/5755 
rs6760120 IL1 Ligand (PSD4) 0.020 1.49 (1.06, 2.21) 0.33 0.92 (0.77, 1.09) 0.19 9/7713 
rs12712122 IL1 Receptor (IL1R2) 0.0031 1.71 (1.21, 2.41) 0.04 1.32 (1.03, 1.69) 0 9/7710 
rs4851531 IL1 Receptor (IL1R2) 0.0087 1.59 (1.11, 2.28) 0.58 0.97 (0.86, 1.09) 0.13 9/7708 
Omoyinmi et. al. 
rs1400986 IL-10 Family (IL20) 0.0004 1.53 (1.21, 1.93) 0.27 1.11 (0.93, 1.32) 0.48 8/7519 
rs4129024 IL-10 Family (MAPKAPK2) 0.0027 0.68 (0.53, 0.88) 0.05 0.87 (0.75, 1.00) 0.08 9/7712 
Fife et. al.  
rs1800896 IL-10 Family (IL10) 0.031 1.34 (n.p.) 0.02 1.15 (1.02, 1.28) 0 9/7716 
rs1400986 IL-10 Family (IL20) 0.028 1.51 (n.p.) 0.27 1.11 (0.93, 1.32) 0.48 8/7519 
Fishman et. al. rs1800795 IL6 0.03 n.p. 0.34 0.94 (0.84, 1.06) 0.32 9/7710 
Hinks et. al. 
rs2071374 IL1A 0.001 1.50 (1.16, 1.92) 0.11 1.11 (0.98, 1.25) 0 9/7711 
rs11836136 MVK 0.03 1.34 (1.03, 1.74) 0.58 1.05 (0.89, 1.23) 0 9/7717 
Scheibel et. al. rs333 CCR5 0.004 n.p. 0.16 0.86 (0.69, 1.06) 0.63 4/7009 
De Benedetti et. al. rs755622 MIF 0.017 n.p. 0.11 0.88 (0.76, 1.03) 0 8/7513 
Lamb et. al. 
rs1541915 SLC26A2 0.0003 2.3 (1.4, 3.7) 0.76 0.98 (0.87, 1.11) 0.19 8/7516 
rs245056 SLC26A2 0.00002 2.8 (1.7, 4.6) 0.72 1.03 (0.86, 1.23) 0.26 8/7513 
rs245055 SLC26A2 0.004 2.5 (1.2, 5.0) 0.56 0.95 (0.81, 1.12) 0 9/7709 
rs245051 SLC26A2 0.0005 2.3 (1.4, 3.7) 0.42 0.95 (0.85, 1.07) 0.44 9/7708 
rs245076 SLC26A2 0.0015 2.7 (1.3, 5.6) 0.46 0.94 (0.80, 1.11) 0 9/7715 
rs8073 SLC26A2 0.04 2.3 (0.9, 5.6) 0.25 0.91 (0.77, 1.07) 0 9/7714 
Bukulmez et. al. rs2071888 TAPBP 0.04 (TDT) n.p. 0.15 1.09 (0.97, 1.22) 0 9/7715 
SNP, single nucleotide polymorphism; INCHARGE, International Childhood Arthritis Genetic Consortium; OR, odds ratio, 95 CI, 95% confidence interval; i2, i2 test 
for heterogeneity; N, number of strata included in meta-analysis; n, number of samples included in meta-analysis; n.p., not provided; TDT, transmission 
disequilibrium testing  
Table 2. Association of IL1RN SNPs with sJIA risk and their effect on IL1RN expression / IL-1RA concentration 
     
IL1RN in LCLs 
Lappalainen et al.25 
IL1RN in whole blood 
Westra et al. 26 
IL-1RA in serum 
















rs55663133 AAT 5.9 x 10-5 1.3 (1.1, 1.4) 1 1.0 x 10-6 -0.25     
rs62158854 G 7.2 x 10-5 1.3 (1.1, 1.4) 1 6.5 x 10-7 -0.25     
rs62158853 T 8.3 x 10-5 1.3 (1.1, 1.4) 1 2.6 x 10-7 -0.26     
rs55709272 C 2.8 x 10-4 1.2 (1.1, 1.4) 0.87       
rs7580634 T 3.7 x 10-4 1.2 (1.1, 1.4) 0.91 2.8 x 10-6 -0.24     
rs4251961 C 4.6 x 10-4 1.2 (1.1, 1.4) 0.86 1.0 x 10-6 -0.25 1.6 x 10-11 -6.74 2.2 x 10-34 -0.08 
rs555447483 A 5.0 x 10-4 1.2 (1.1, 1.4) 0.89       
rs28648961 A 8.5 x 10-4 1.2 (1.1, 1.4) 0.75 2.8 x 10-6 -0.24     
rs111354213 - 9.8 x 10-4 1.2 (1.1, 1.4) 0.74       
rs6743171 C 1.1 x 10-3 1.2 (1.1, 1.4) 0.77 3.2 x 10-6 -0.24 5.8 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs17207494 C 1.1 x 10-3 1.2 (1.1, 1.4) 0.75 2.9 x 10-6 -0.24 3.8 x 10-8 -5.50 1.3 x 10-11 -0.08 
rs10171849 C 1.1 x 10-3 1.2 (1.1, 1.4) 0.75 5.5 x 10-6 -0.23 2.6 x 10-8 -5.57 1.4 x 10-11 -0.08 
rs4496335 T 1.2 x 10-3 1.2 (1.1, 1.4) 0.77 3.0 x 10-6 -0.24 5.2 x 10-8 -5.44 6.4 x 10-13 -0.09 
rs6730516 T 1.2 x 10-3 1.2 (1.1, 1.4) 0.77 3.5 x 10-6 -0.24 6.2 x 10-8 -5.41 6.4 x 10-13 -0.09 
rs55896126 C 1.2 x 10-3 1.2 (1.1, 1.4) 0.75 2.7 x 10-6 -0.24     
rs6734238 G 1.2 x 10-3 1.2 (1.1, 1.4) 0.73   2.4 x 10-8 -5.58 1.1 x 10-12 -0.08 
rs13410964 A 1.2 x 10-3 1.2 (1.1, 1.4) 0.77 2.7 x 10-6 -0.24 6.4 x 10-8 -5.41 6.4 x 10-13 -0.09 
rs13424580 A 1.2 x 10-3 1.2 (1.1, 1.4) 0.75 2.4 x 10-6 -0.24 5.3 x 10-8 -5.44 1.4 x 10-11 -0.08 
rs1446510 T 1.2 x 10-3 1.2 (1.1, 1.4) 0.77 2.8 x 10-6 -0.24 6.2 x 10-8 -5.41 6.5 x 10-13 -0.09 
rs10176274 G 1.3 x 10-3 1.2 (1.1, 1.4) 0.77 2.7 x 10-6 -0.24 5.8 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs10188292 T 1.3 x 10-3 1.2 (1.1, 1.4) 0.77 2.6 x 10-6 -0.24 5.8 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs1446509 T 1.3 x 10-3 1.2 (1.1, 1.4) 0.77 2.0 x 10-6 -0.24 6.2 x 10-8 -5.41 6.5 x 10-13 -0.09 
rs62158846 T 1.3 x 10-3 1.2 (1.1, 1.4) 0.75       
rs6738239 A 1.3 x 10-3 1.2 (1.1, 1.4) 0.77 4.7 x 10-6 -0.23 6.1 x 10-8 -5.42 6.5 x 10-13 -0.09 
rs13382561 G 1.3 x 10-3 1.2 (1.1, 1.4) 0.75 1.9 x 10-6 -0.24 3.7 x 10-8 -5.51 1.4 x 10-11 -0.08 
rs7587033 G 0.001296 1.2 (1.1, 1.4) 0.77 2.9 x 10-6 -0.24     
rs6750559 A 0.001325 1.2 (1.1, 1.4) 0.77 2.5 x 10-6 -0.24 6.1 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs7574427 A 0.001344 1.2 (1.1, 1.4) 0.77 2.1 x 10-6 -0.24 4.3 x 10-8 -5.48 1.4 x 10-11 -0.08 
rs6722922 T 0.001374 1.2 (1.1, 1.4) 0.77 2.7 x 10-6 -0.24 6.1 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs6741180 A 0.001376 1.2 (1.1, 1.4) 0.77 3.1 x 10-6 -0.24 6.0 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs7574159 A 0.001393 1.2 (1.1, 1.4) 0.75 2.1 x 10-6 -0.24 5.3 x 10-8 -5.44 1.2 x 10-11 -0.08 
rs13398728 C 0.001434 1.2 (1.1, 1.4) 0.77 2.7 x 10-6 -0.24 6.0 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs13409371 A 0.001445 1.2 (1.1, 1.4) 0.79 6.3 x 10-7 -0.25 5.2 x 10-9 -5.84 3.8 x 10-12 -0.08 
rs13409360 A 0.001467 1.2 (1.1, 1.4) 0.79 6.5 x 10-7 -0.25 3.8 x 10-9 -5.89 7.8 x 10-13 -0.08 
rs12329129 A 0.001468 1.2 (1.1, 1.4) 0.77 2.8 x 10-6 -0.24 6.1 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs12328368 G 0.001473 1.2 (1.1, 1.4) 0.77 2.7 x 10-6 -0.24 6.1 x 10-8 -5.42 6.4 x 10-13 -0.09 
rs7596350 G 0.001475 1.2 (1.1, 1.4) 0.75 1.7 x 10-6 -0.24     
rs6746979 A 0.001485 1.2 (1.1, 1.4) 0.75 2.1 x 10-6 -0.24 5.1 x 10-8 -5.45 1.4 x 10-11 -0.08 
rs58865280 A 0.001494 1.2 (1.1, 1.4) 0.75       
rs9973741 G 0.001514 1.2 (1.1, 1.4) 0.75 2.1 x 10-6 -0.24     
rs12328766 G 0.001562 1.2 (1.1, 1.4) 0.77 3.0 x 10-6 -0.24 6.2 x 10-8 -5.41 6.4 x 10-13 -0.09 
rs550593914 T 0.001593 1.2 (1.1, 1.4) 0.77       
SNP, single nucleotide polymorphism; Meta P, fixed effect meta-analysis P value; Meta OR, fixed effect meta-analysis odds ratio; 95 CI, 95% 
confidence interval; r2, pairwise r2 with rs55663133 using the Estimation-Maximization method in the U.S. case-control population; LCL, lymphoblastoid 
cell line.  The top 7 sJIA-associated SNPs, which are inherited as an LD block, are shown in bold italics.
Table 3. Association between sJIA-associated quantitative trait loci for IL1RN expression (and 
serum levels of IL-1RA protein) and response to anakinra therapy in 38 patients from the 









(n=29) P value OR (95CI) 
rs55663133 - 0.67 0.22 1.6 x 10-2 7.0 (1.3, 36.7) 
rs62158854 T 0.67 0.22 1.6 x 10-2 7.0 (1.3, 36.7) 
rs62158853 C 0.67 0.24 2.1 x 10-2 6.3 (1.2, 32) 
rs55709272 T 0.67 0.1 9.8 x 10-4 17.3 (2.8, 108.1) 
rs7580634 G 0.67 0.1 9.8 x 10-4 17.3 (2.8, 108.1) 
rs4251961 T 0.78 0.21 1.8 x 10-3 13.4 (2.2, 82) 
rs555447483 - 0.71 0.08 7.7 x 10-4 28.7 (3.2, 255.8) 
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